Stay updated with breaking news from Affera Mapping. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medtronic's SPHERE Per-AF study results reveal the Sphere-9 Catheter's superior safety and efficacy in treating persistent atrial fibrillation compared to the Thermocool SmartTouch SF. The Sphere-9 offers advanced mapping and ablation, showing higher freedom from AFib and fewer complications.
Medtronic (NYSE: MDT) announced data showing the safety and efficacy of its Affera mapping and ablation system with the Sphere-9 catheter.
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The
The company — which is headquartered out of Fridley, Minnesota — is set to bring treatment for atrial fibrillation to market next year
12-month results reinforce versatility and durability for the treatment of paroxysmal and persistent AFib with the first-of-its-kind pulsed field ablation, radiofrequency, and high density mapping Sphere-9 Catheter